OS Therapies Appoints Borys Shor, PhD to ADC Advisory Board
22 Agosto 2024 - 7:00AM
Business Wire
OS Therapies (NYSE American: OSTX) (“OS Therapies” or “the
Company”), an ADC and Immunotherapy research and clinical-stage
biopharmaceutical company, today announced that it has appointed
Borys Shor, PhD to its Antibody Drug Conjugate (ADC) Advisory
Board. In his role, Dr. Shor will assist the Company in the
selection of antibody and payloads to be developed using the
Company’s tunable ADC platform leveraging its proprietary
pH-sensitive SiLinker™ silicone linker technology.
Dr. Shor has 20 years of experience in leading oncology
discovery programs and external R&D partnerships at large
pharma (Pfizer, Wyeth) and biotech companies, with specific focus
on preclinical discovery and development of small molecule kinase
inhibitors, biologics and nanoparticles. He is a founder and the
CEO of Manhattan BioSolutions Inc. Dr. Shor also serves as a
BioEntrepreneur-In-Residence with the Long Island Bioscience Hub
and is a founder of BioIDEA, a biotech pitching forum in New York
City. Previously at Pfizer, Boris led cross-functional oncology
research teams to develop novel antibody-drug conjugates and
supported Biological License Application (BLA) filing for
Inotuzumab, which was approved for the treatment of leukemia in
2017. Prior to that, Dr. Shor served as a project team leader at
the department of Oncology Discovery at Wyeth Pharmaceuticals,
managing the discovery and characterization of novel kinase
inhibitors for the treatment of cancer.
He currently serves on the executive management team of
early-stage biotech companies and is a life sciences investment
advisor for a biotech hedge fund. Dr. Shor earned MS degree in
molecular genetics from the St. Petersburg State University. He
also received a PhD in Molecular and Cell Biology at the SUNY
Downstate Medical Center and performed a postdoctoral fellowship in
the Inflammation Research team at Johnson & Johnson
Pharmaceutical R&D prior to joining Wyeth.
About OS Therapies
OS Therapies is a clinical stage oncology company focused on the
identification, development and commercialization of treatments for
Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company’s
lead asset, is an immunotherapy leveraging the immune-stimulatory
effects of Listeria bacteria to initiate a strong immune response
targeting the HER2 protein. The Company has completed enrollment
for a 41-patient Phase 2b clinical trial of OST-HER2 in resected,
recurrent osteosarcoma, with results expected in the fourth quarter
of 2024. OST-HER2 has completed a Phase 1 clinical study primarily
in breast cancer patients, in addition to showing strong
preclinical efficacy data in various models of breast cancer. In
addition, OS Therapies is advancing its next generation Antibody
Drug Conjugate (ADC) platform, known as tunable ADC (tADC), which
features tunable, tailored antibody-linker-payload candidates. This
platform leverages the Company’s proprietary silicone linker
technology, enabling the delivery of multiple payloads per linker.
For more information, please visit www.ostherapies.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240822112221/en/
Corporate and Media Contact: Jack Doll 410-297-7793
irpr@ostherapies.com Investor Relations: Dave Gentry RedChip
Companies, Inc. 1-407-644-4256 OSTX@redchip.com
OS Therapies (AMEX:OSTX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024
OS Therapies (AMEX:OSTX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024
